Previous 10 | Next 10 |
Blueprint Medicines (NASDAQ:BPMC) stock fell ~9% on June 9 after the company said that it will swap the objectives of a key study of its medicine Ayvakit after recommendation from the U.S. Food and Drug Administration (FDA) The company is evaluating Ayvakit (avapritinib) in a t...
Gainers: Bluejay Diagnostics BJDX +29%. DBV Technologies DBVT +12%. Arcellx (ACLX) +10%. Immix Biopharma (IMMX) +10%. AbCellera Biologics (ABCL) +8%. Losers: Precision BioSciences (DTIL) -10%. Blueprint Medicines (BPMC) -9%. Hutchmed (China) (HCM)&...
Blueprint Medicines Reports Continued Progress Toward Goal of Transforming Treatment of Systemic Mastocytosis PR Newswire -- New analyses showing AYVAKIT® (avapritinib) significantly improved overall survival in advanced SM, when indirectly compared to real-world ...
Update 12:15pm: Updates shares, adds other potential names benefitting from the deal. Blueprint Medicines (NASDAQ:BPMC) rose 4% after Bristol Myers (BMY) agreed to acquire Turning Point Therapeutics (TPTX) for over $4B in cash. Stifel said in a note that buy-rated Blueprint (BPMC) c...
Blueprint Medicines (NASDAQ:BPMC) rose 1.2% in premarket trading, after Bristol Myers (BMY) agreed to acquire Turning Point Therapeutics (TPTX) for over $4B in cash. Stifel said in a note that buy-rated Blueprint (BPMC) came first to mind after Bristol agreed to buy TPTX. Blue...
Jefferies has upgraded Blueprint Medicines (NASDAQ:BPMC) to Buy from Hold as the commercial-stage biotech prepares to report topline data for registration-enabling PIONEER trial for Ayvakit in non-advanced (Indolent) systemic mastocytosis (ISM) in late summer 2022. A rare genetically driven c...
A lot of small biotechs are fantastic buys right now. With Big Pharma sitting on a lot of cash, we might start seeing some smart acquisitions later this year. We asked a trio of contributors to pick the biotechs they're feeling most bullish about as potential buyout candidates in 2022. ...
Blueprint Medicines Corporation (BPMC) Q1 2022 Earnings Conference Call May 3, 2022 8:30 AM ET Company Participants Jenna Cohen - Senior Director and Head of Investor Relations Kate Haviland - Chief Executive Officer Christy Rossi - Chief Operating Officer Philina Lee - Chief Commercial Offic...
Blueprint Medicines press release (NASDAQ:BPMC): Q1 GAAP EPS of -$1.79 beats by $0.10. Revenue of $62.73M (+190.7% Y/Y) beats by $22.75M. For further details see: Blueprint Medicines GAAP EPS of -$1.79 beats by $0.10, revenue of $62.73M beats by $22.75M
Blueprint Medicines Reports First Quarter 2022 Results PR Newswire -- Achieved $23.8 million in AYVAKIT ® (avapritinib) net product revenues, and $62.7 million in total revenues -- -- AYVAKYT® (avapritinib) launch in Germany underway f...
News, Short Squeeze, Breakout and More Instantly...
Blueprint Medicines Corporation Company Name:
BPMC Stock Symbol:
NASDAQ Market:
Blueprint Medicines Corporation Website:
2024-05-13 18:15:03 ET Stephens analyst issues OVERWEIGHT recommendation for BPMC on May 13, 2024 04:31PM ET. BPMC was trading at $108.05 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 6 - Buy, 3 - Hold ...
2024-05-09 15:34:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
A look at the top 10 most actives in the United States Jaguar Health Inc. (JAGX) rose 30.3% to $0.2932 on volume of 173,918,707 shares Emergent Biosolutions Inc. (EBS) rose 71.0% to $3.3 on volume of 150,987,238 shares PROSHARES TRUST (SQQQ) fell 3.6% to $11.78 on volume of 136,332,744 sh...